Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets

Pulmonary Circulation

Volumn 2, Issue 2, 2012, Pages 193-200

  Hirenallur S , Dinesh K ^a   Detweiler, Neil D ^a   Haworth, Steven T ^b,c   Leming, Jeaninne T ^b   Gordon, John B ^b,d   Rusch, Nancy J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Department of Medicine ^*  (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Furegrelate; Hypoxia; Neonatal pulmonary arterial hypertension; Pulmonary arterial hypertension; Thromboxane A2; Thromboxane synthase; Vasoconstriction

Indexed keywords

EID: 85015324449     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.97605     Document Type: Article

References (32)

1. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007;91:283-290.
2. Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003;21:155-76.
3. Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: Inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clin Perinatol 2012;39:149-64.
4. Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Eur J Clin Invest 2006;36 Suppl 3:16-24.
5. Adatia I, Barrow SE, Stratton P, Ritter JM, Haworth SG. Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J 1993;69:179-82.
6. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
7. Fuse S, Kamiya T. Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation 1994;90:2952-5.
8. Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993;88:2117-22.
9. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704.
10. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.
11. Rich S, Hart K, Kieras K, Brundage BH. Thromboxane synthetase inhibition in primary pulmonary hypertension. Chest 1987;91:356-60.
12. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002;143:E4.
13. Hamberg M, Samuelsson B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci USA 1973;70:899-903.
14. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975;72:2994-8.
15. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004;36:1187-205.
16. Fike CD, Kaplowitz MR, Pfister SL. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am J Physiol 2003;284:L316-23.
17. Fike CD, Zhang Y, Kaplowitz MR. Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets. J Appl Physiol 2005;99:670-6.
18. Fike CD, Aschner JL, Slaughter JC, Kaplowitz MR, Zhang Y, Pfister SL. Pulmonary arterial responses to reactive oxygen species are altered in newborn piglets with chronic hypoxia-induced pulmonary hypertension. Pediatr Res 2011;70:136-41.
19. Gorman RR, Johnson RA, Spilman CH, Aiken JW. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3’-pyridinylmethyl) benzofuran-2-carboxylate. Prostaglandins 1983;26:325-42.
20. Mohrland JS, VanderLugt JT, Gorman RR, Lakings DB. Thromboxane synthase activity and platelet function after furegrelate administration in man. J Clin Pharmacol 1989;29:53-8.
21. Mohrland JS, VanderLugt JT, Lakings DB. Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects. Eur J Clin Pharmacol 1990;38:485-8.
22. Lakings DB, Friis JM, Lunan CM, VanderLugt JT, Mohrland JS. Pharmacokinetics of furegrelate after oral administration to normal humans. Pharm Res 1989;6:53-7
23. Wynalda MA, Liggett WF, Fitzpatrick FA. Sodium 5-(3’-pyridinylmethyl) benzofuran-2-carboxylate (U-63557A), a new, selective thromboxane synthase inhibitor: Intravenous and oral pharmacokinetics in dogs and correlation with ex situ thromboxane B2 production. Prostaglandins 1983;26:311-24.
24. Hirenallur SD, Haworth ST, Leming JT, Chang J, Hernandez G, Gordon JB, et al. Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. Am J Physiol 2008;295:L915-24.
25. Perneby C, Granstrom E, Beck O, Fitzgerald D, Harhen B, Hjemdahl P. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B2 in urine: Comparison with GC-MS. Thromb Res 1999;96:427-36.
26. Molthen RC, Karau KL, Dawson CA. Quantitative models of the rat pulmonary arterial tree morphometry applied to hypoxia-induced arterial remodeling. J Appl Physiol 2004;97:2372-2384;discussion 2354.
27. Bui KC, Hammerman C, Hirschl R, Snedecor SM, Cheng KJ, Chan L, et al. Plasma prostanoids in neonatal extracorporeal membrane oxygenation. Influence of meconium aspiration. J Thorac Cardiovasc Surg 1991;101:612-7.
28. Dobyns EL, Wescott JY, Kennaugh JM, Ross MN, Stenmark KR. Eicosanoids decrease with successful extracorporeal membrane oxygenation therapy in neonatal pulmonary hypertension. Am J Respir Crit Care Med 1994;149:873-80.
29. Pakala R, Benedict CR. Effect of serotonin and thromboxane A2 on endothelial cell proliferation: Effect of specific receptor antagonists. J Lab Clin Med 1998;131,527-37.
30. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997;96,2280-6.
31. Sachinidis A, Flesch M, Ko Y, Schror K, Bohm M, Dusing R, et al. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 1995;26,771-80.
32. Fediuk J, Gutsol A, Nolette N, Dakshinamurti S. Thromboxane-induced actin polymerization in hypoxic pulmonary artery is independent of Rho. Am J Physiol Lung Cell Mol 2012;302:L13-26.